Title: Correlation between nonalcoholic fatty liver disease and left ventricular diastolic
dysfunction in non-obese adults: a cross-sectional study
Version: 2 Date: 27 Oct 2022
Reviewer's report:
Authors state that....Obesity is related to higher all-cause mortality, so both obese and non-
obese NAFLD patients can benefit from losing weight. For non-obese NAFLD patients, losing
weight by 5-10% through lifestyle intervention can also benefit significantly......but they should
honestly recognise that there are many drugs on the pipeline that are reckoned as good candidates
to cure NAFLD/NASH, and consequently to reduce the burden of  CV diseases  linked to
this very common illness, as evident in various recent papers, for example...Insights into the
molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver
disease. Metabolism. 2022 Jan;126:154925. doi: 10.1016/j.metabol.2021.154925. Epub 2021
Nov 2. PMID: 34740573.
Data on visceral adiposity should be presented , such as WC or WHR, to better evaluate its role
in the so-called non-obese subjects (BMI<25), who can be overweight according to cut-offs of
the BMI of the Chinese population.
Data on insulin resistance (such as HOMA or other indices) should be presented to   try
to clarify  the possible mechanisms of the early left ventricular diastolic dysfunction...as
evident in... Early subclinical ventricular dysfunction in patients with insulin resistance. J
Cardiovasc Med (Hagerstown). 2014 Feb;15(2):110-4. doi: 10.2459/JCM.0b013e3283638164.
PMID: 24522082.
Authors should deepen the concept of age that is a risk factor for the progression of both CV
diseases via atherosclerosis and NAFLD , according to their findings, see ORs of the multiple
regression.
Title: Correlation between nonalcoholic fatty liver disease and left ventricular diastolic
dysfunction in non-obese adults: a cross-sectional study
Version: 2 Date: 27 Oct 2022
Reviewer's report:
Authors state that....Obesity is related to higher all-cause mortality, so both obese and non-
obese NAFLD patients can benefit from losing weight. For non-obese NAFLD patients, losing
weight by 5-10% through lifestyle intervention can also benefit significantly......but they should
honestly recognise that there are many drugs on the pipeline that are reckoned as good candidates
to cure NAFLD/NASH, and consequently to reduce the burden of  CV diseases  linked to
this very common illness, as evident in various recent papers, for example...Insights into the
molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver
disease. Metabolism. 2022 Jan;126:154925. doi: 10.1016/j.metabol.2021.154925. Epub 2021
Nov 2. PMID: 34740573.
Data on visceral adiposity should be presented , such as WC or WHR, to better evaluate its role
in the so-called non-obese subjects (BMI<25), who can be overweight according to cut-offs of
the BMI of the Chinese population.
Data on insulin resistance (such as HOMA or other indices) should be presented to   try
to clarify  the possible mechanisms of the early left ventricular diastolic dysfunction...as
evident in... Early subclinical ventricular dysfunction in patients with insulin resistance. J
Cardiovasc Med (Hagerstown). 2014 Feb;15(2):110-4. doi: 10.2459/JCM.0b013e3283638164.
PMID: 24522082.
Authors should deepen the concept of age that is a risk factor for the progression of both CV
diseases via atherosclerosis and NAFLD , according to their findings, see ORs of the multiple
regression.
Please review this paper.
user
Title: Correlation between nonalcoholic fatty liver disease and left ventricular diastolic
dysfunction in non-obese adults: a cross-sectional study
Version: 2 Date: 27 Oct 2022
Reviewer's report:
Authors state that....Obesity is related to higher all-cause mortality, so both obese and non-
obese NAFLD patients can benefit from losing weight. For non-obese NAFLD patients, losing
weight by 5-10% through lifestyle intervention can also benefit significantly......but they should
honestly recognise that there are many drugs on the pipeline that are reckoned as good candidates
to cure NAFLD/NASH, and consequently to reduce the burden of  CV diseases  linked to
this very common illness, as evident in various recent papers, for example...Insights into the
molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver
disease. Metabolism. 2022 Jan;126:154925. doi: 10.1016/j.metabol.2021.154925. Epub 2021
Nov 2. PMID: 34740573.
Data on visceral adiposity should be presented , such as WC or WHR, to better evaluate its role
in the so-called non-obese subjects (BMI<25), who can be overweight according to cut-offs of
the BMI of the Chinese population.
Data on insulin resistance (such as HOMA or other indices) should be presented to   try
to clarify  the possible mechanisms of the early left ventricular diastolic dysfunction...as
evident in... Early subclinical ventricular dysfunction in patients with insulin resistance. J
Cardiovasc Med (Hagerstown). 2014 Feb;15(2):110-4. doi: 10.2459/JCM.0b013e3283638164.
PMID: 24522082.
Authors should deepen the concept of age that is a risk factor for the progression of both CV
diseases via atherosclerosis and NAFLD , according to their findings, see ORs of the multiple
regression.
assistant